천식 치료의 최신지견 ; 지속성베타2항진제(LABA)의 안전성

• Published in: The Korean journal of medicine Vol. 80; no. 2; pp. 135 - 138
• Main Authors: 이병재, Byung Jae Lee
• Format: Journal Article
• Language: Korean
• Published: 대한내과학회 01.02.2011
• Subjects: Asthma; Inhaled corticosteroid; LABA; Long-acting beta2-agonist; 지속성베타2항진제; 천식; 흡입스테로이드
• ISSN: 1738-9364

A recent meta-analysis of clinical trials found that long-acting beta2-agonists (LABA) increased life-threatening asthma exacerbations and deaths, which led to warnings concerning regular use of LABA by U.S. Food and Drug Administration (FDA). It is now obvious that LABA monotherapy in asthma increases the risk of serious adverse events. However, the risk is reduced with concomitant use of inhaled corticosteroid (ICS). Hence the FDA`s recommendations that LABA should not be used in patients whose asthma is well controlled with a medium dose of ICS, or LABA should be withdrawn once asthma control is achieved, remain still controversial. It seems reasonable to follow current guidelines which recommend the use of LABA when asthma is not controlled with ICS, although more well-designed research on the safety of LABA, especially when combined with ICS, is required. (Korean J Med 2011;80:135-138)